methylphenidate has been researched along with Anorexia in 17 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Response to methylphenidate is associated with higher baseline fatigue but not with higher baseline depression or sedation." | 3.77 | Factors associated with response to methylphenidate in advanced cancer patients. ( Bruera, E; Chacko, R; Palmer, JL; Yennurajalingam, S, 2011) |
| "Depression is quite common among cancer patients." | 2.73 | An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. ( Elbi, H; Ersoy, MA; Noyan, AM, 2008) |
| " Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events." | 2.72 | Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. ( Bukstein, O; Greenhill, L; Lerner, M; McBurnett, K; McGough, JJ; Stein, M; Wilens, TE, 2006) |
| " Pulse, blood pressure, and the presence of treatment emergent adverse events (AEs), parent and teacher AE ratings, and vital signs were recorded in each phase." | 2.72 | Safety and tolerability of methylphenidate in preschool children with ADHD. ( Abikoff, H; Chuang, S; Davies, M; Ghuman, J; Greenhill, L; Kollins, S; McCRACKEN, J; McGOUGH, J; Posner, K; Riddle, M; Skrobala, A; Stehli, A; Swanson, J; Thorp, B; Vitiello, B; Wigal, S; Wigal, T, 2006) |
| "Methylphenidate also has an adverse event profile that requires consideration." | 2.41 | How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. ( King, J; Langford, S; Moher, D; Pham, B; Schachter, HM, 2001) |
| " Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer." | 1.36 | Methylphenidate side effects in advanced cancer: a retrospective analysis. ( Davis, MP; Khoshknabi, DS; Lasheen, W; Mahmoud, F; Rivera, N; Walsh, D, 2010) |
| " Medication dosing was flexible, with titration to a maximum of 30 mg/day." | 1.35 | The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate. ( Fried, J; Greenhill, L; Gugga, SS; Maayan, L; Paykina, N; Strauss, T, 2009) |
| " Members of the high-dose group (n = 58) had received at least 1 stimulant at a dosage > or = 120% of the maximum recommended by the American Academy of Sleep Medicine Standards of Practice Committee." | 1.33 | Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. ( Auger, RR; Goodman, SH; Krahn, LE; Pankratz, VS; Silber, MH; Slocumb, NL, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (29.41) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Espadas, M | 1 |
| Insa, I | 1 |
| Chamorro, M | 1 |
| Alda-Diez, JA | 1 |
| Na, KS | 1 |
| Lee, SI | 1 |
| Hong, SD | 1 |
| Kim, JH | 1 |
| Shim, SH | 1 |
| Choi, J | 1 |
| Yang, J | 1 |
| Lee, MS | 1 |
| Joung, YS | 1 |
| Kim, EJ | 1 |
| Park, JH | 1 |
| Maayan, L | 1 |
| Paykina, N | 1 |
| Fried, J | 1 |
| Strauss, T | 1 |
| Gugga, SS | 1 |
| Greenhill, L | 3 |
| Lasheen, W | 1 |
| Walsh, D | 1 |
| Mahmoud, F | 1 |
| Davis, MP | 1 |
| Rivera, N | 1 |
| Khoshknabi, DS | 1 |
| Yennurajalingam, S | 1 |
| Palmer, JL | 1 |
| Chacko, R | 1 |
| Bruera, E | 1 |
| Auger, RR | 1 |
| Goodman, SH | 1 |
| Silber, MH | 1 |
| Krahn, LE | 1 |
| Pankratz, VS | 1 |
| Slocumb, NL | 1 |
| McGough, JJ | 1 |
| McBurnett, K | 1 |
| Bukstein, O | 1 |
| Wilens, TE | 1 |
| Lerner, M | 1 |
| Stein, M | 1 |
| Wigal, T | 1 |
| Chuang, S | 1 |
| McGOUGH, J | 1 |
| Vitiello, B | 1 |
| Skrobala, A | 1 |
| Swanson, J | 1 |
| Wigal, S | 1 |
| Abikoff, H | 1 |
| Kollins, S | 1 |
| McCRACKEN, J | 1 |
| Riddle, M | 1 |
| Posner, K | 1 |
| Ghuman, J | 1 |
| Davies, M | 1 |
| Thorp, B | 1 |
| Stehli, A | 1 |
| Ersoy, MA | 1 |
| Noyan, AM | 1 |
| Elbi, H | 1 |
| Rosse, RB | 1 |
| Licamele, WL | 1 |
| Golinko, BE | 2 |
| Schachter, HM | 1 |
| Pham, B | 1 |
| King, J | 1 |
| Langford, S | 1 |
| Moher, D | 1 |
| Antelman, SM | 1 |
| Caggiula, AR | 1 |
| Black, CA | 1 |
| Edwards, DJ | 1 |
| Eckerman, DA | 1 |
| Moy, SS | 1 |
| Perkins, AN | 1 |
| Patrick, KS | 1 |
| Breese, GR | 1 |
| Dulcan, MK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Learning Skill After OROS Methylphenidate Treatment in Adolescents With Attention-Deficit/Hyperactivity Disorder: A 12-week, Multi-center, Open-label Study[NCT01060150] | Phase 4 | 115 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Long-Duration Stimulant Treatment of ADHD in Young Children-Feasibility Study[NCT00257725] | Phase 4 | 11 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Methylphenidate Efficacy and Safety in ADHD Preschoolers[NCT00018863] | Phase 3 | 165 participants | Interventional | 2001-04-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 2.14 |
"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Higher scores indicate worsening." (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 2.81 |
The K-ARS is a rating scale that is used for the ADHD diagnosis and the assessment of treatment efficacy and comprises 18 items in total on the basis of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), each item being rated from 0-3 points. The total score ranges from 0-54 with 0=normal and 54=severe condition. (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 11.78 |
The LST measures learning ability of student. This scale is composed of 7 sections: self control, participation, task accomplishment, reading, writing, test taking and information processing. It consists of 70 items for middle school student (age 13-15 years) and 80 items for high school student (age 16-18 years). Each item is rated on a 5-point Likert scale ranging from 1 (never) to 5 (always). The total score range is 70-350 for middle school version and 80-400 for high school version where higher score indicates better ability for learning. In result analysis, each sub-score and total score was converted to T-score for normalization. The score range of T-score is from 1 to 100 with a mean of 50. Higher score indicates better ability for learning. (NCT01060150)
Timeframe: Week 12
| Intervention | T-score (Mean) |
|---|---|
| OROS Methylphenidate HCl | 49.61 |
The ADS is composed of 4 factors: omission/missing frequency to measure attention dispersibility; false alarm/commission frequency to measure impulse; mean response/reaction time to measure the speed of task processing; and the response variability/standard deviation of response time to measure the consistency of attention. The total value for both, omission errors and commission errors, ranges from 0-100 errors where high value indicates worsening attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Errors (Mean) | |||
|---|---|---|---|---|
| Omission errors: Baseline | Omission errors: Week 12 | Commission errors: Baseline | Commission errors: Week 12 | |
| OROS Methylphenidate HCl | 58.88 | 57.40 | 62.98 | 51.70 |
The ADS is composed of 4 factors: omission/missing frequency to measure attention dispersibility; false alarm/comission frequency to measure impulse; mean response/reaction time to measure the speed of task processing; and the response variability/standard deviation of response time to measure the consistency of attention. The score range for both, reaction time and response variability, is 0-100. High score indicates worsening attention. If one or over factor's score is over 65 point, the participant is resulted in having attention deficit. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on scale (Mean) | |||
|---|---|---|---|---|
| Reaction time average: Baseline | Reaction time average: Week 12 | Response variability: Baseline | Response variability: Week 12 | |
| OROS Methylphenidate HCl | 54.32 | 49.73 | 85.77 | 59.42 |
This test measures the executive function of the frontal lobe and is consisted of examinations of category/meaning fluency and letter/phoneme fluency. It consisted of three 60 second word generation trials in which the participant orally generates as many words as possible that begin with target letters F, A and S. Dependent variables included total number of acceptable words generated for each target letter and total number of words generated across all three letter trials. Total score was calculated as sum of acceptable words generated, with higher scores indicating better verbal fluency. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Words (Mean) | |||
|---|---|---|---|---|
| Category/semantic: Baseline | Category/semantic: Week 12 | Letter/phenomic: Baseline | Letter/phenomic: Week 12 | |
| OROS Methylphenidate HCl | 29.71 | 30.62 | 28.71 | 33.78 |
Each participant individually was given a sequence of numbers, with the sequence becoming progressively longer, to repeat the digits in the same sequence, either forwards or backwards. Each sequence length was attempted twice. The test was complete after failure on both trials of any sequence length. 1 point was awarded if the participant passed only 1 trial of a sequence length. 0 points were given if the participant failed both trials. Total score range was 0-16 (forwards) and 0-14 (backwards). A higher score was indicative of better recall and attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Forward: Baseline | Forward: Week 12 | Backward: Baseline | Backward: Week 12 | |
| OROS Methylphenidate HCl | 11.19 | 11.56 | 7.09 | 7.32 |
In FW test, a participant shows memory of a demonstrated visual pattern using a 8x11 inch plastic template containing 9 asymmetrically located holes. The examiner models a given sequence of holes and asks the participant to imitate the sequence by placing his/her finger through the same holes in the correct order. The total number of correct sequences constitutes the total score which ranges from 0-24 (forward FW) and 0-28 (backward FW) with higher score indicating a more favorable health state. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Forward FW: Baseline | Forward FW: Week 12 | Backward FW: Baseline | Backward FW: Week 12 | |
| OROS Methylphenidate HCl | 18.42 | 19.09 | 15.59 | 17.36 |
This test consists of 3 trials: color trial (simple execution), word trial (middle execution) and word-color interference trial (interfering execution). In simple execution, participants have to read the written color names of the words independent of the color of the ink. In middle execution, participants have to read words written in black letters. In interfering experiment, participants have to say the color of the letters independent of the written word. The total value ranges from 0-24 errors for each execution where high value indicates worsening attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Errors (Mean) | |||||
|---|---|---|---|---|---|---|
| Simple execution false reaction: Baseline | Simple execution false reaction: Week 12 | Middle execution false reaction: Baseline | Middle execution false reaction: Week 12 | Interfering execution false reaction: Baseline | Interfering execution false reaction: Week 12 | |
| OROS Methylphenidate HCl | 0.4 | 0.16 | 0.3 | 0.2 | 1.04 | 0.84 |
This test consists of 3 trials: color trial (simple execution), word trial (middle execution) and word-color interference trial (interfering execution). In simple execution, participants have to read the written color names of the words independent of the color of the ink. In middle execution, participants have to read words written in black letters. In interfering experiment, participants have to say the color of the letters independent of the written word. This test estimates spending time for execution. High spending time indicates low ability of suppression of automation. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Simple execution time: Baseline | Simple execution time: Week 12 | Middle execution time: Baseline | Middle execution time: Week 12 | Interfering execution time: Baseline | Interfering execution time: Week 12 | |
| OROS Methylphenidate HCl | 14.78 | 13.64 | 15.88 | 15.04 | 22.12 | 19.72 |
Ratio interference is calculated by dividing simple execution time by interfering execution time. The score range is 0-1. Higher value indicates better ability of suppression of automation. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| OROS Methylphenidate HCl | 0.70 | 0.72 |
Children's Global Assessment Scale (C-GAS) is designed to assess overall functioning across settings. The scale is rated from 1 to 100, with lower scores reflecting poorer adjustment. Change from baseline is reported. (NCT00257725)
Timeframe: week 5
| Intervention | score on a scale (Mean) |
|---|---|
| ADHD Treatment Group | 10.55 |
"CGI-S is designed to assess severity of illness on a seven-point scale: 1 = normal (not at ll ill) to 7 = among the most extremely ill patients.~Range: 0-7, higher score means worse outcome. Change from baseline is reported." (NCT00257725)
Timeframe: week 5
| Intervention | score on a scale (Mean) |
|---|---|
| ADHD Treatment Group | -1.64 |
"The SNAP-IV Rating Scale is a revision of the Swanson, Nolan and Pelham (SNAP) Questionnaire (Swanson et al, 1983). The SNAP-IV is based on a 0 to 3 rating scale: Not at All = 0, Just A Little = 1, Quite A Bit = 2, and Very Much = 3. Subscale scores on the SNAP-IV are calculated by summing the scores on the items in the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item, as shown for ratings on the ADHD-Inattentive (ADHD-I) subset.~Sub scale ranges from 0-3. Higher scores mean better outcome. Change score from baseline is reported." (NCT00257725)
Timeframe: week 5
| Intervention | score on a scale (Mean) |
|---|---|
| ADHD Treatment Group | -1.09 |
2 reviews available for methylphenidate and Anorexia
| Article | Year |
|---|---|
[Side effects of methylphenidate in children and the young].
Topics: Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Bone Diseases, Developmental; C | 2018 |
How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis.
Topics: Adolescent; Adult; Age Factors; Anorexia; Attention Deficit Disorder with Hyperactivity; Bias; Centr | 2001 |
5 trials available for methylphenidate and Anorexia
| Article | Year |
|---|---|
Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: an open-label study.
Topics: Administration, Oral; Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Child; De | 2013 |
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2006 |
Safety and tolerability of methylphenidate in preschool children with ADHD.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, P | 2006 |
An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antidepressive Agents, Tricyclic; Depressive Disorder; | 2008 |
Side effects of dexedrine in hyperactive children: operationalization and quantification in a short-term trial.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Dextroamphetamine; Dose | 1982 |
10 other studies available for methylphenidate and Anorexia
| Article | Year |
|---|---|
The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, P | 2009 |
Methylphenidate side effects in advanced cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anorexia; Central Nervous System Stimulants | 2010 |
Factors associated with response to methylphenidate in advanced cancer patients.
Topics: Anorexia; Anxiety; Central Nervous System Stimulants; Depression; Drug Monitoring; Dyspnea; Fatigue; | 2011 |
Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study.
Topics: Adult; Anorexia; Case-Control Studies; Central Nervous System Stimulants; Disorders of Excessive Som | 2005 |
Slow-release methylphenidate: problems when children chew tablets.
Topics: Abdomen; Anorexia; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations | 1984 |
Side effects of dextroamphetamine and methylphenidate in hyperactive children--a brief review.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Dextroamphetamine; Grow | 1984 |
Another long-acting methylphenidate (Metadate CD).
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clinical Trials as | 2001 |
Stress reverse the anorexia induced by amphetamine and methylphenidate but not fenfluramine.
Topics: Animals; Anorexia; Dextroamphetamine; Dose-Response Relationship, Drug; Feeding and Eating Disorders | 1978 |
Enantioselective behavioral effects of threo-methylphenidate in rats.
Topics: Animals; Anorexia; Appetite; Appetite Depressants; Behavior, Animal; Male; Methylphenidate; Rats; Re | 1991 |
Attention deficit disorder: evaluation and treatment.
Topics: Age Factors; Anorexia; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Body Height; | 1985 |